Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.73) by 28.77 percent. This is a 62.59 percent increase over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $960.999 thousand which missed the analyst consensus estimate of $1.900 million by 49.42 percent. This is a 27.18 percent decrease over sales of $1.320 million the same period last year.